; and (B) drugs and biological products— (i) approved under sections 505 and 564 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 355 and 360bbb–3) for SARS–CoV–2 or COVID–19; or (ii) licensed under section 351 of the Public Health Service Act ( 42 U.S.C. 262 ) for the cure, mitigation, or treatment of SARS–CoV–2 or COVID–19; and (6) carry out other activities related to such testing, as determined by the Secretary. (d) Consideration In establishing the grant program under subsection (a), the Secretary shall take into consideration COVID–19 testing plans required under the fourth proviso under the second paragraph under the heading Department of Health and Human Services—Office of the Secretary—Public Health and Social Services of title 1 of division B of the Paycheck Protection Program and Health Care Enhancement Act ( Public Law 116–139 ). (e) Priority In awarding grants pursuant to this section, the Secretary shall give priority to eligible entities that serve— (1) communities that have limited access to transportation, including communities— (A) with a high percentage of households that do not have access to private vehicles; (B) that do not have public transit; (C) with a high percentage of individuals who primarily use public transit for transportation; or (D) with reduced access to public transit as a result of the spread of COVID–19; (2) medically underserved populations (as defined in section 330(b)(3) of the Public Health Service Act (42 U.S.C 254b(b)(3)))